Skip to main content

Day: February 8, 2020

Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020

Written by Customer Service on . Posted in Public Companies.

— Robust efficacy with evidence of a dose response —— 6/6 patients rescue-injection-free in cohort 1, with 3 patients at 52 weeks — — 4/6 patients rescue-injection-free in cohort 2 (lower dose) at 24 weeks —— Company to host and webcast a discussion with key opinion leaders Sunday, February 9, at 10:00 am EST —REDWOOD CITY, Calif., Feb. 08, 2020 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new interim clinical data from the OPTIC Phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy. OPTIC includes treatment-experienced patients with wet age-related macular degeneration (AMD). The data are being presented today...

Continue reading

Nidec Announces Outlines of Planned Stock Split, Amendment to Articles of Incorporation, and Modification to Share Repurchase Program

Written by Customer Service on . Posted in Public Companies.

KYOTO, Japan, Feb. 08, 2020 (GLOBE NEWSWIRE) — Nidec Corporation (TSE: 6594; OTC US: NJDCY) (the “Company”) today announced that the Board of Directors of the Company, at a meeting held on February 8, 2020, made the following decisions regarding a stock split and an amendment to the Company’s Articles of Incorporation, as well as a modification to the Company’s share repurchase program resolved on January 23, 2020.1. Purposes of the Stock SplitThe Company has decided to implement a stock split to enhance the liquidity of the Company’s common stock and expand its investor base by reducing the trading price per share of the Company’s common stock.2. Outline of the Stock Split3. Amendment to the Article of Incorporation 4. Modification to the Share Purchase Program (Reference)Details...

Continue reading

Mitek Appoints Aaron Korsen as Vice President, North American Identity Sales

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) — Mitek Systems, Inc. (NASDAQ: MITK, www.miteksystems.com), a global leader in mobile capture and digital identity verification solutions, announced today that Aaron Korsen has been named Senior Vice President, North American Identity Sales.Most recently, Aaron led the North America sales operation for the Netsuite services.  Prior to Netsuite, Aaron led global sales for Kenandy, a SalesForce Ventures and Lightspeed-backed ERP software company. Before joining Kenandy, Aaron was Executive Vice President of Sales and Marketing at Luxent, a Salesforce.com service partner and application developer.  Korsen also spent 23 years at Epicor Software where he was the Senior Vice President of Sales and Marketing for its retail division (currently operating as Aptos) and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.